Vascular
The latest sourced reporting on Vascular from Dementias Today: dated, and plain about what the evidence does and does not show.
COSMOS tested a daily multivitamin against placebo in more than 21,000 American seniors and found a small, repeatable slowing of cognitive aging. It is one of the only supplement results in dementia prevention that has held up, and it is smaller than the headlines suggest.
A narrative review published on October 20 inventories where generative AI already touches Alzheimer's work. The uses furthest along are the ones no family ever sees: synthetic notes, phenotype mining from visit records, and drafted summaries. None of it has been tested in a live clinic.
A new review proposes that expecting to think clearly, or expecting to fail, draws on the same limited pool of mental control the task itself needs. The evidence is thin in exactly the places families care about most, and the authors say so.
A triple-blind trial at UZ Leuven randomises colon-release short-chain fatty acid capsules against placebo, then injects every volunteer with bacterial endotoxin and measures what happens to working memory, inhibition and task switching. It is a cause test in a field built mostly on correlations.
A new scoping review pulls 108 studies on gardens, green space and outdoor programs into one picture. What it shows is real. What it leaves blank matters just as much.
Nine Italian memory clinics signed up to test whether a structured daily diary of behaviour beats standard care at lightening the load on families. Three years after the trial was registered, the results have not appeared.
A peer reviewed protocol lays out a 160 person randomized trial testing whether a mobile app, Brain CareNotes, that structures what family care partners report about behavioral symptoms of Alzheimer's and related dementias eases caregiver burden and those symptoms. The trial is still enrolling; no effectiveness results exist yet.
A small randomized trial of 36 caregiver-dyads in South Korea found that a mobile app translating caregiver-logged behavior into individualized, nonpharmacological activity suggestions was associated with lower overall behavioral and psychological symptoms, less agitation and depression, better nighttime sleep efficiency, and higher caregiver confidence, researchers reported.
In a Taipei scanner, 31 healthy adults were given the same electric jolt over and over. What changed how much it hurt was not how reliable their expectation was, but how much feeling it carried. For anyone thinking about pain and dementia, that difference matters.
At a cognitive neurology clinic, a voice AI ran the long history-taking interview while patients waited for their testing. A peer-reviewed SIGDIAL 2026 paper reports what it caught, and what it still cannot tell anyone.
A cluster-randomized trial in 38 primary care clinics is testing whether an alert built into the electronic health record can help clinicians catch cognitive impairment they might otherwise miss, with the first published results in on clinician confidence, not on diagnosis rates.
A pooled analysis of brain-scan data from 409 people finds that words alone and words paired with conditioning change pain-related brain activity in overlapping but partly different ways, a distinction researchers say matters for how future placebo-based protocols are designed and tested.
A February 2026 Nature review by Henrik Zetterberg and Barbara Bendlin gathers the scattered story of blood and spinal fluid tests across Alzheimer's and other neurodegenerative dementias, and shows plainly where the map runs out.
A UK feasibility study wore blinded Dexcom G7 sensors on 32 older inpatients with type 2 diabetes and cognitive impairment for up to 10 days, testing whether continuous glucose monitoring can be deployed on the ward at all, before any question of whether it changes outcomes.
A review in Alzheimer's & Dementia maps how falling NAD+ and the body's 24-hour timing machinery pull on each other in dementia. It is a map of mechanisms, not a treatment.
A study using smart ring data from 162 older adults found that variability in nightly sleep and heart rate patterns, tracked over months, distinguished mild cognitive impairment better than single average readings.
A two-sample Mendelian randomization study reports that genetically predicted obstructive sleep apnea is tied to lower, not higher, odds of a general dementia diagnosis, a finding that runs against decades of observational research and that its own authors say needs replication.
A global records analysis built to compare new melatonin users against new benzodiazepine and zolpidem users for dementia and Parkinson's disease outcomes found the reverse of the hoped-for result: melatonin starters had higher rates of diagnosis, not lower.
An audit of records at one large academic health system found that a diagnosis of dementia or cognitive impairment barely moves the odds a caregiver has been granted shared access to a patient's electronic health record portal, a gap researchers say undercuts every other tool built on top of it.
A long-term follow-up of the DREAMS START trial found that sleep improvements in people with dementia were still detectable 24 months after the program began, though the family caregivers' own sleep did not improve.
A new scoping review catalogs 43 studies of AI tools built for family caregivers of people with Alzheimer's disease and related dementias, from robots to chatbots. The authors found a wide range of functions on offer and called for rigorous, long-term testing that so far has not been done.
A widely used diabetes medicine shifted the molecular profile of old mice across heart, muscle, blood and brain. The signal ran through the hypothalamus, and it looked strikingly like the effect of blocking mTOR. This is mouse biology, not a dementia treatment.
A study in Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring tested clinical decision-support software that reads laboratory values, medications and vital signs, not just diagnosis codes, to surface treatable conditions that may be worsening cognitive impairment in older adults.
A Dutch laboratory trial found that openly telling healthy volunteers a device could not hurt them, paired with a symptom-reversing procedure, eased artificially induced pain sensitivity as well as or better than concealing that information. The method has not been tested in patients, older adults, or anyone with a dementia.
A 262-caregiver randomized trial of WeCareAdvisor, the web app that turns a caregiver's plain-language account of a behavior into a tailored, physician-shareable plan, found a modest but statistically significant drop in caregiver distress by three months. Two of its three prespecified primary measures, confidence and the behaviors themselves, showed no significant difference between groups.
A circuit-mapping study in mice found that a context paired with morphine later produced about half the drug's own pain relief, with the brain releasing its own opioids. A commentary in Current Biology says it is time to rethink what morphine's numbers in trials actually measure, including in studies of pain and agitation in dementia.
An analysis of the long-running ARIC cohort found that sleep measures pulled from a chest-worn heart monitor, including how much bedtime shifted night to night, tracked with later dementia diagnoses in older adults who wore the device for roughly two weeks in 2016 and 2017.
A newly published study protocol describes a three year effort in South Korea to follow community dwelling seniors with mild cognitive impairment using wrist actigraphy, sweat patch sampling and indoor sensors, alongside yearly home visits, with the goal of building machine learning models of who progresses to dementia.
A memory clinic team at the University of Virginia drafted a short survey to gauge how ready a care partner feels to plan ahead. The instrument exists on paper. It has not yet been given to a single caregiver in a validation study.
In a Padua laboratory, 102 young adults were handed sham lenses and a story about what they would do. The story alone moved their reading speed. Not their mood: their output.
Three months after opening the rewrite for public comment, HHS has formally issued its 2026 Update to the National Plan to Address Alzheimer's Disease and Related Dementias, restructuring federal priorities around risk reduction, research, care and family support.
At a Copenhagen memory clinic, a handheld torch and seven days of motion sensors were asked to forecast the next year of Alzheimer's disease. Neither one asked the patient to remember anything.
A lab study combining EEG, pupil tracking and behavioral testing found that when a sensory event matched what people expected, they judged its location faster, but recalled the exact spot less precisely, a pattern the researchers say reveals two separate brain processes, not one.
A nationwide study of more than 2,000 older insulin users with Alzheimer disease and related dementias found that those wearing a continuous glucose monitor had a 43 percent lower death rate and fewer hospital stays than those checking blood sugar with fingersticks, though several related safety measures did not reach statistical significance.
A preprint trains a 7 billion parameter reasoning model on the real hospital notes of roughly 3,000 patients, then asks it where the illness is heading. The work is retrospective and unreviewed, and it is franker about its own failure modes than most papers of its kind.
Governor Kathy Hochul has signed a law forcing New York's long-term care hotline, NY Connects, to actively point callers toward Alzheimer's and dementia programs rather than leaving them to ask. The catch: nothing changes for a full year.
In a 274-person trial spanning 43 countries, dementia caregivers who used a self-guided, chatbot-driven psychoeducation program called PDC30 reported less depression and less burden after one month than those left on a waiting list. No clinician ever entered the exchange.
A Mayo Clinic-led study of more than 3,100 older adults finds that glucose activity in two separate white matter tracts, read on FDG-PET scans, predicts how fast cognition changes in the years ahead, adding information that gray matter scans and amyloid tests do not capture on their own.
On one morning in 1947, 70,805 Scottish schoolchildren sat the same test. Decades on, some of them donated their brains. In the fastest decliners the myelin was thicker, the fibres were thinner, and the cells that lay down the insulation look like participants in the damage.
A new legal analysis walks through every place in the world where voluntary assisted dying is lawful and finds that a dementia diagnosis, by itself, almost never clears the bar, even in the handful of countries that allow a person to request it in advance.
Across four hospitals and 70 clinics in Hawaii, an ambient AI scribe drafted more than 25,000 real visit notes in three months. It gave clinicians back time. Whether a caregiver's account arrives intact in the note is a question nobody has asked yet.
Twenty-two health and social care professionals across England describe, in a new qualitative study, how people with dementia who live alone with no family or friend nearby can vanish from the system's view at every stage, from the first missed sign to the day they go home from hospital with no one waiting.
A Lancet Psychiatry review maps the ways a clinician's wording shapes what a patient feels, and asks which of those ways survive telling the patient everything
Geneticists chasing clues in blood, pathologists reading brain tissue, and researchers watching rats with narrowed arteries all landed on the same molecule, COX5B, as diminished in vascular dementia. Three other candidates did not survive the trip intact.
The National Institute for Health and Care Research has extended its Policy Research Unit at the University of Exeter with 2 million pounds and two extra years, stretching its mandate past dementia and neurodegeneration to cover more of the neurological conditions families live with.
A new discussion paper from the FDA's Digital Health Center of Excellence sketches a way to grade generative AI tools by risk, but it never says whether software that turns a caregiver's daily notes into a clinician's summary counts as a medical device at all. The public has until October 19 to weigh in.
DemMA, published in the Findings of ACL 2026, puts a simulated person with dementia in the chair so trainees can practise the conversation: nine subtypes, nonverbal cues, 2,709 synthetic dialogues, and not one real patient in the data.
A JAMA audit of every AI device the FDA has authorized for Alzheimer's disease and related dementias found the paperwork behind them seldom names the patients the software learned from. Race and ethnicity appeared for at most one device per source.
A policy paper from the Global Brain Health Institute and Aga Khan University makes the case that poverty, wealth shocks, income inequality and HIV belong among the modifiable dementia risks, and that their absence tilts prevention toward risks more common in men.
The Massachusetts House voted unanimously on July 29, 2026 to require acute care hospitals to notify a designated family member or caregiver soon after a dementia patient is admitted and again before discharge. The bill, which also expands diagnosis notification and creates a new MassHealth care coordination benefit, now heads to the Senate.
Governor Wes Moore has signed a law replacing Maryland's lone dementia director with a full state program, and ordered health officials to find out whether the state's clinicians are actually ready for the patients already walking into their offices.
H.R.6130 would give Medicare, for the first time, legal authority to cover blood-based screening for Alzheimer's disease and related dementias. The bill sets January 1, 2028 as the earliest possible start date, a date that holds only if the measure becomes law.
A regional midterm review of the UN Decade of Healthy Aging finds that the share of countries in the Americas with a national long-term-care policy jumped from 61 percent to 88 percent since 2020, but the money and services to make those policies real have not kept pace, with direct consequences for how dementia care gets funded and staffed.
UK Research and Innovation has launched the Dementia Challenge, funding real-world NHS trials of faster MRI scans, blood tests and remote cognitive assessments, with a target of diagnosing 92% of referred patients within 18 weeks, up from about 60% today.
A cluster-randomized trial of nearly 34,000 rural Chinese adults found a 15 percent lower rate of dementia after seven years in villages where non-physician health workers managed blood pressure, extending earlier four-year findings from the same program.
Two Mount Sinai studies using engineered human brain tissue report that APOE4, the strongest genetic risk factor for Alzheimer's, drives a specific, experimentally reversible pattern of blood vessel scarring and protein buildup, distinct from the gene's broader population-level risk.
A propensity-matched study of more than 21,000 Taiwanese adults with type 2 diabetes found GLP-1 receptor agonists nearly halved the risk of an overall dementia diagnosis compared with long-acting insulin, but the benefit vanished when Alzheimer's disease and vascular dementia were analyzed on their own.
A bill introduced in the Senate would credit hours spent bathing, medicating and transporting a relative with an age-related condition toward eligibility for bigger retirement contributions, but it is still sitting in committee with no vote scheduled.
H.R. 3747 would add dementia care to the list of specialty topics eligible for federal Project ECHO training grants and reauthorize the program through 2031, but it has not become law.
The Credit for Caring Act, reintroduced in the House and Senate in March 2025, would create a new federal tax credit of up to $5,000 for working family caregivers. More than a year later, the bipartisan bill remains in committee with no vote scheduled.